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AbstrACt
background Antimicrobial resistance (AMR) is a global 
health priority. Leading UK and global strategy papers to 
fight AMR recognise its social and behavioural dimensions, 
but current policy responses to improve the popular use 
of antimicrobials (eg, antibiotics) are limited to education 
and awareness-raising campaigns. In response to 
conceptual, methodological and empirical weaknesses 
of this approach, we study people’s antibiotic-related 
health behaviour through three research questions. RQ1: 
What are the manifestations and determinants of 
problematic antibiotic use in patients’ healthcare-seeking 
pathways? RQ2: Will people’s exposure to antibiotic 
awareness activities entail changed behaviours that diffuse 
or dissipate within a network of competing healthcare 
practices? RQ3: Which proxy indicators facilitate the 
detection of problematic antibiotic behaviours across and 
within communities?
Methods We apply an interdisciplinary analytical 
framework that draws on the public health, medical 
anthropology, sociology and development economics 
literature. Our research involves social surveys of 
treatment-seeking behaviour among rural dwellers in 
northern Thailand (Chiang Rai) and southern Lao PDR 
(Salavan). We sample approximately 4800 adults to 
produce district-level representative and social network 
data. Additional 60 cognitive interviews facilitate 
survey instrument development and data interpretation. 
Our survey data analysis techniques include event 
sequence analysis (RQ1), multilevel regression 
(RQ1–3), social network analysis (RQ2) and latent class 
analysis (RQ3).
Discussion Social research in AMR is nascent, but our 
unprecedentedly detailed data on microlevel treatment-
seeking behaviour can contribute an understanding of 
behaviour beyond awareness and free choice, highlighting, 
for example, decision-making constraints, problems of 
marginalisation and lacking access to healthcare and 
competing ideas about desirable behaviour.
trial registration number NCT03241316; Pre-results.
bACkgrounD
Access to non-prescription antibiotics is a 
widespread phenomenon in low-income 
Summary box
 ► Antimicrobial resistance (AMR) is a global health 
priority, and leading UK and global strategy papers 
recognise its social and behavioural dimensions.
 ► Behavioural elements of these strategy papers 
have conceptual, methodological and empirical 
weaknesses.
 ► We will carry out social research to understand 
the nature of antibiotic-related treatment-seeking 
behaviour in rural Thailand and Lao PDR.
 ► We will conduct survey research with 4800 adult 
villagers (yielding district-level representative and 
social network data), complemented with cognitive 
interviews and secondary administrative data.
 ► Our study will contribute to the nascent yet urgently 
needed social research in AMR.
 o
n
 6 August 2018 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2017-000621 on 28 March 2018. Downloaded from 
2 Haenssgen MJ, et al. BMJ Glob Health 2018;3:e000621. doi:10.1136/bmjgh-2017-000621
BMJ Global Health
and middle-income countries (LMICs),1 contributing 
to inappropriate medicine use, to the development of 
antimicrobial resistance (AMR) and potentially to the 
subsequent spread of resistant bacteria across the world.2 
Leading global and UK policy papers aiming to deal 
with the overuse and misuse of antibiotics among the 
general population focus thereby wholly on educational 
and awareness-raising campaigns to encourage positive 
behaviour change.3–6 Awareness raising is important,7 but 
as the sole global strategy focusing on people’s health-
care-seeking behaviour (aside from public health inter-
ventions to prevent illness), it has three central weak-
nesses.
The first is conceptual: by limiting our attention to 
‘awareness’ as the main driver of people’s antibiotic 
use, we are prone to neglecting determinants of health 
behaviour beyond information and free choice such as 
economic constraint, social pressure or local conceptions 
of illness.8–11 However, little is known about how economic 
constraints, social discrimination or spatial marginalisa-
tion deprive people of choices and drive them into seem-
ingly adverse antibiotic-related behaviours, and whether 
and how interventions should address these constraints 
in the context of global AMR policy.
The second is methodological: quantitative commu-
nity-level and population-level analyses of antibiotic 
usage disregard routinely that healthcare processes 
involve combinations of ‘no care’, ‘self-care’ and 
healthcare from many different practitioners.12 
Although conceptually established and applied in 
qualitative research,13 14 the sequential understanding 
of treatment-seeking behaviour has not yet entered 
quantitative public health research. The majority of 
quantitative analyses of healthcare behaviour in LMICs 
instead adopt a single-stage approach, implying that a 
patient ‘chooses’ once from a portfolio of healthcare 
options, some of which may be more likely to involve 
antibiotics than others.15 16 This conventional analysis 
can be useful to measure rates of antibiotic access, but 
their aggregate nature forgoes valuable information 
and obscures the factors influencing antibiotic use 
throughout an illness, for example, the use of informa-
tion technology to gather information (as we demon-
strate in Haenssgen and Ariana17).
The third is empirical: studies of awareness campaign 
effectiveness focus on knowledge gains but disregard 
the social mechanisms of information diffusion (see, 
eg, Onnela et al18). Awareness campaigns often expect 
information to spread within communities, but these 
communities are not always collaborative.19 In addition, 
as a potential solution in a healthcare-seeking problem, 
new information about antibiotic use also competes with 
other ideas, some of which may represent dominant 
healthcare strategies from the individual’s perspective.20i 
i Information is also unlikely to remain static during the diffusion 
process; utilisation and (re-)interpretation of educational messages 
can alter nature, meaning and value of this information over time and 
We do not understand sufficiently how these interdepen-
dencies play out during the diffusion process of antibi-
otic knowledge and practice. It therefore appears risky to 
confine our behavioural tactics to the single mechanism 
of awareness raising that is merely believed to function.
In response to these conceptual, methodological and 
empirical challenges, we intend to improve the under-
standing of patients’ antibiotic-related behaviour to 
support creative thinking about targeted and unconven-
tional AMR interventions in LMICs. Three research ques-
tions will guide our enquiry.
RQ1: What are the manifestations and determinants of 
problematic antibiotic use in patients’ healthcare-seeking 
pathways?
RQ2: Will people’s exposure to antibiotic awareness 
activities entail changed behaviours that diffuse or dissi-
pate within a network of competing healthcare practices?
RQ3: Which proxy indicators facilitate the detection 
of problematic antibiotic behaviours across and within 
communities?
We adhere to conventions in the field of public health 
when using the contentious language of ‘problematic’ 
and ‘appropriate’ behaviour. However, from a behavioural 
perspective, a conventional clinical definition of ‘prob-
lematic behaviour’ is impractical to pursue because 
it would involve claims on the mis/match between a 
patient’s condition (eg, being caused by a particular 
microorganism) and the type, dosage, duration and 
affordability of the administered drugs. Patients are not 
necessarily able to diagnose themselves, decide whether 
an antibiotic is needed and then select the clinically most 
suitable course of treatment. Indeed, many illnesses do 
not involve a doctor at all. Considering that ‘problematic 
behaviour’ is subjective and context specific, we instead 
record patients’ behavioural trajectories during an illness 
and apply different evaluative criteria to make judge-
ments of ‘appropriateness’ flexibly and transparently. 
In consultation with the social anthropologists, medical 
practitioners and local field staff in our study team, we 
will categorise individually as well as socially ‘appropriate’ 
behavioural sequences that go beyond binary assessments 
of healthcare access or antibiotic use. For example, indi-
vidually rational bypassing of referral systems could entail 
healthcare resource misallocation from a public health 
perspective, and individual antibiotic use can entail nega-
tive externalities on the societal level through potential 
contributions to antibiotic resistance. Our interest in 
human behaviour thereby does not intend to attribute 
blame to patients for patterns of antibiotic usage that 
might contribute to AMR, but rather to explore deci-
sions and decision-making constraints on the healthcare 
across people. Our focus on healthcare-seeking behaviour and attitudes 
towards antibiotics can capture unintended behavioural responses to a 
limited extent, but our survey is unable to study the implications and 
mechanisms underlying such potential transformations comprehen-
sively (for which qualitative and ideally ethnographic research would be 
better suited). We thank an anonymous reviewer for pointing this out.
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demand side. The provision of the raw behavioural 
sequences will allow other researchers to make their own 
evaluations of health behaviours depending on their 
specific assessment criteria and interests.
MetHoDs
theoretical framework
Our study departs from conventional policy assumptions 
that antibiotic misuse among patients stems from a lack of 
knowledge regarding appropriate medicine use. Instead, 
we frame antibiotic use as one among multiple solutions 
in people’s healthcare ‘activity space’.
Contrary to existing applications of activity space 
frameworks in areas like disability and mobility21–23 
and social geography,24–26 we do not adhere to spatial 
conceptualisations through which, for example, expe-
rienced space is linked to health outcomes like obesity 
or HIV.24 26 Instead, we draw on theoretical strands and 
techniques from the disciplines of public health, medical 
anthropology, sociology and development economics, 
which suggest that healthcare behaviour takes place 
within a physical and social space populated by various 
healthcare providers (including drug vendors), and that 
this space is defined by the difficulty and the perceived 
and dynamically changing value of utilising any of these 
providers during an illness. Difficulty is determined by 
the tools and solutions at the patients’ disposal (eg, social 
support networks, cars, communication technology), but 
not every solution affects access to different providers 
equally. In addition, patients might not be aware of every 
provider in their vicinity (they therefore do not enter the 
activity space), and some providers signal better health-
care value than others, depending on type and severity 
of the illness. Moreover, the activity space overlaps across 
patients and it is thus a shared space. These characteris-
tics lead us to identify three key elements of antibiotic 
usage in a healthcare activity space: (1) the emergence 
of pathways through the health system during the course 
of an illness; (2) the coexistence of multiple solutions for 
the health problem, the value of which changes dynam-
ically and (3) cooperation, competition and exclusion 
in a shared social space. As a result, our definition of 
activity spaces can be likened to ‘markets’ in the strategic 
marketing literature,27 where markets can be delineated 
by different customer groups (in the case of health, eg, 
different socioeconomic groups), the customer function 
to be served (eg, curative care) and the ‘alternative solu-
tions’ available to fulfil this function (eg, antibiotic use at 
home, care from primary health centre, sick leave).
The breadth of the activity space framework allows us 
to consider multiple, and otherwise conceptually more 
restricted, explanatory approaches for treatment-seeking 
behaviour side-by-side (eg, transaction cost approaches 
alongside the information deficit arguments that often 
underlie policy narratives).28 29 The conceptualisation 
as a shared social space also permits us to go beyond 
conventional individualistic treatment-seeking models in 
order to explore new forms of health-related collective 
action problems. In addition, our framework permits us 
to examine the determinants of problematic behaviour 
and the positive as well as negative outcomes of tech-
nology use, rather than merely articulating the enabling 
conditions of desired behaviour change as is common in 
the public health literature.30–32 Activity spaces are there-
fore not a theory per se, but a useful analytical domain to 
guide our research.
research design
We will carry out population-level and community-level 
health behaviour surveys in rural Chiang Rai (Thailand) 
and Salavan (Lao PDR) and we collect complemen-
tary qualitative data. This will result in two survey data 
sets: the first contains district-level representative treat-
ment-seeking behaviour of approximately 1200 adults 
across 30 rural communities per country; the second 
comprises social network censuses of approximately 
400 adults each in three rural communities per country. 
Within the sampled villages, we will complete checklists 
about existing formal and informal healthcare facilities 
and gather patient load data from primary care units 
catering to the respective villages. As part of the ques-
tionnaire testing process, we will conduct (and collect as 
primary data) cognitive interviews to improve the survey 
tool and to interpret our data.
We will carry out the district-level village survey in one 
round and the village-level social network censuses in two 
rounds (see figure 1; source: authors). Between the two 
village social network censuses, we will carry out educa-
tion activities in the selected villages as part of antibiot-
ic-related and medicine-use-related public engagement. 
Developed after a year of qualitative health behaviour 
research across Southeast Asia, these small-scale activities 
aim to help villagers learn more about drug resistance 
and to help the social and medical research communities 
to better appreciate local people’s access to healthcare 
and medicine conceptions and constraints. The activi-
ties will take place after the network surveys in each of 
the network villages, lasting 1–2 days, involving approx-
imately 30 villagers each, and including interactive 
sessions like trading games, poster making, storytelling, 
and role  plays.ii The district survey will take place after 
the education activities, and we will subsequently resurvey 
all adults in the network villages (ie, 2–3 months after the 
first network village survey round).
study participants
Groups included in this research comprise adults (aged 
18 years and above) in rural Salavan and rural Chiang 
Rai. We focus on Thailand and Lao PDR because they are 
ii While we do not expect regular social networks to evolve as a result of 
our educational activity, we will be able to ascertain whether people acti-
vate different social contacts when seeking treatment before and after 
our activity. In addition, we will also learn whether respondents who did 
not participate in the activity learnt about it through their regular social 
network or from other contacts.
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situated in a region that experiences high rates of antibi-
otic use and increasing resistance.4 33 34 Compared with 
Lao PDR, Thailand exhibits a more advanced economic 
and health system context and more established AMR 
stewardship. A comparative study of these LMIC contexts 
(Lao PDR and Thailand) therefore offers interesting 
lessons for domestic and global antibiotic policy. We focus 
on adults because they account for much of the popular 
antibiotic demand and typically acquire and admin-
ister antibiotics on behalf of children.35 Lastly, we focus 
on rural areas of Chiang Rai and Salavan because their 
formal and informal health systems face relatively high 
Figure 2 Field sites and sampled villages in Thailand and Lao PDR.
Figure 1 Study design and timeline.
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infrastructural, human resource, financial and regulatory 
constraints; while their inhabitants are more often char-
acterised by economic, social and spatial marginalisation. 
This does not automatically mean that our entire study 
population qualifies as ‘marginalised’ since we define 
marginalisation in relative terms of wealth (eg, bottom 
quintiles of household asset and amenity indices), social 
position (eg, within village social networks) and geog-
raphy (eg, distance to urban centres). However, it is 
important to note that our study implications will speak 
to rural areas with their specific constraints and patterns 
of marginalisation, which are systematically different 
from urban settings.
Data collection
The district-level representative survey will be conducted 
in a three-stage stratified cluster random sampling 
design. A cluster sample is necessary to ensure the logis-
tical and financial feasibility of the survey, and we aim to 
reduce its negative implications for the effective sample 
size through stratification, which helps to increase the 
information contained in each cluster.36 The first stage 
involves the random selection of 30 villages (clusters) 
across five purposively selected districts in each site, strat-
ified by their distance to the nearest urban centre (using 
data from National Geospatial Intelligence Agency37). 
Figure 2 depicts the resulting village samples (source: 
authors, adapted from Google38 2017 map data from 
Landsat/Copernicus). The second stage enumerates all 
residential buildings within the selected villages using 
satellite imagery from Google Maps and Bing Maps, of 
which we sample 5% of the buildings (but at least 30 
houses) in a stratified interval sampling approach to 
ensure spatial representativeness. During the survey 
implementation, the third sampling stage will select 
randomly one respondent for every five adults in each 
chosen house.
The sampling strategy for the community-level social 
network census surveys involves the purposive selection 
of three comparable villages in both countries. Selected 
in consultation with local stakeholders, guiding criteria 
for selection were (1) village size and structure, (2) 
remoteness and road accessibility, (3) economic status as 
approximated by village-level infrastructure and facilities, 
(4) ethnic composition and (5) number and location of 
health facilities within a 2 km radius. The villages are esti-
mated to have a size of 100–200 households with 2.9 adults 
per rural household in Lao PDR (ranging from 1.8 to 
4.6 per village) and 2.4 in Thailand on average (ranging 
from 1.6 to 4.3 per village).39 40 Within the selected 
communities, all households will be approached, their 
adult members enumerated and invited to participate.
Our survey instrument will be a 45 min questionnaire 
that captures people’s complex healthcare-seeking 
pathways and their medicine use therein. An important 
feature of this instrument is the collection of self-re-
ported sequential healthcare pathway data for acute 
illnesses and accidents that occurred in the 2 months 
prior to the interview. As shown in figure 3 (source: 
authors, adapted from Haenssgen and Ariana41), we will 
subdivide an illness into discrete steps of activities and 
record their type, duration and location; with whom the 
patient interacted during the healthcare activity; whether 
the patient used any medicines during the step (elicited 
using a ‘drug card’ containing the most common local 
medicines), their source, and how long, often, and at 
what dosage they were taken and whether, why, and by 
whom any kind of health-related mobile phone, Internet, 
media or vehicle use took  place.iii We also collect data 
on the social and economic background of the respon-
dents as well as information about people’s existing 
conceptions of and attitudes towards antibiotics. In the 
case of the social network censuses, we will ask additional 
iii Due to language ambiguities in the term ‘antibiotic,’ we do not ask 
people directly whether they took an antibiotic, but rather which 
medicine they received and used at each step in the treatment-seeking 
process. Pilot interviews suggested that a part of the rural population is 
able to describe medicine unambiguously (eg, using colloquial or tech-
nical terms for antibiotics), while other groups do not know what medi-
cine they received. In the latter case, we triangulate their responses with 
their descriptions of antibiotics (eg, as ‘sore throat medicine’, which we 
also capture in the questionnaire), and we ask for descriptions of these 
medicines (eg, ‘a shot’, ‘a green-blue capsule’). We then code the medi-
cines for sensitivity analysis into categories ‘likely to be an antibiotic’, 
‘unlikely to be an antibiotic’ and ‘cannot ascertain type of medicine’ 
according to common medicines used in the field sites.
Figure 3 Example of treatment-seeking pathway data collected in the survey.
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questions to construct four different kinds of (health-re-
lated) social networks:
 ► (Health) communication networks: people within 
and outside the village with whom the respondent 
interacts and talks about health (elicited in first net-
work survey round).
 ► Incidence network: places where the respondent typi-
cally interacts with other villagers (elicited in first net-
work survey round).
 ► Help network: contacts who are activated during an 
illness (elicited in both network survey rounds).
 ► Information network: people with whom the respond-
ent talked about the public engagement activity (elic-
ited in second network survey round).
The questionnaire will be administered through tablet-
based electronic data collection by locally recruited survey 
teams comprising six enumerators and two survey super-
visors per country. The survey period will be between 
November 2017 and April 2018, which is the post-rice-
harvest dry season in both field sites. This season was 
chosen for village accessibility (landslides and floods are 
common during the rainy season) and the availability of 
villagers for interviews (villagers often reside temporarily 
near their rice fields during the planting and harvest 
seasons). Due to the temporal focus on one season, our 
survey is therefore not able to capture seasonal change 
affecting the epidemiological environment, internal 
migration, healthcare-seeking patterns and interactions 
within social networks.
We will pilot the questionnaire to identify respondents’ 
understanding of the survey questions and the range of 
possible answers. Between 10 and 30 1 hour cognitive 
interviews per site will support this process and enable 
insights into how respondents understand survey ques-
tions and how they arrive at their answers.42 The qualita-
tive data generated through the cognitive interviews will 
also facilitate the interpretation of the quantitative survey 
results.
Two further sources of data will complement our 
survey data. First, in order to understand antibiot-
ic-seeking behaviour in the local health systems, separate 
checklists will help us to gather observational informa-
tion about the location of formal and informal health-
care providers in each village. Second, we will estimate 
patient load and peak demand for public healthcare 
services by accessing secondary administrative data from 
public primary care facilities that cater to the sampled 
villages.
Analysis
The data analysis techniques to inform our research 
questions include:
 ► RQ1: sequence analysis to describe and understand 
linear series of events.41 43 44
 ► RQ1–3: multilevel regression analysis to test the rela-
tionship between antibiotic use as a dependent varia-
ble and a range of established determinants of treat-
ment-seeking behaviour as independent variables.45
 ► RQ2: social network analysis (network-based event 
history and relational event sequence analysis) to ex-
amine how behaviours and beliefs across a social net-
work relate to individual behaviours and beliefs and 
how this relationship persists over time.46–48 
 ► RQ3: latent class analysis to identify (1) common 
symptoms associated with problematic antibiotic us-
age, (2) the characteristics of populations who are 
likely to exhibit problematic antibiotic behaviours 
and (3) contextual conditions predicting adverse be-
haviours, all of which may help guide future interven-
tions and policies.49
Related in particular to Research Questions 1 and 2, we 
will further examine six hypotheses about antibiotic use 
among the general population.
H1. Marginalised groups have fewer means to access 
formal treatment, which increases their likelihood to rely 
on over-the-counter medicines including antibiotics as an 
alternative solution.
H2. Technology use increases access to formal health-
care providers but is directed towards those who are more 
inclined to prescribe  antibiotics.iv
H3. Awareness about ‘rational antibiotic use’ alone has 
only a minor influence on antibiotic usage behaviour 
if patients are economically, socially or spatially 
marginalised.
H4. In the absence of competing healthcare practices, 
new antibiotic-related behaviours diffuse through social 
networks.
H5. Pre-existing competing practices subdue the 
spread of new antibiotic-related behaviours within the 
community network if no ‘critical mass’ can be achieved.
H6. Peak demand for scarce high-quality healthcare 
providers drives less competitive (ie, more marginalised) 
patients into behaviours that are more likely to involve 
adverse antibiotic use.
Note that these hypotheses do not intend to declare 
the behaviour of marginalised groups to be ‘irrational’. 
Rather, we hypothesise that the behaviour of margin-
alised groups is subject to greater healthcare access 
constraints, owing to which antibiotic use might be more 
likely. Whether this is indeed the case and whether these 
behaviours are less appropriate than otherwise are empir-
ical questions that we hope to inform through our survey.
DisCussion
ethical considerations
Informed consent
We received a waiver for written consent requirements in 
order to not unfairly exclude illiterate population subgroups 
in our field sites50 and to ensure trust between the researcher 
and the rural respondents.51 Instead of participant-dated 
iv The interest in technology use is rooted in our activity space frame-
work, according to which different healthcare providers (eg, private 
doctors) are more responsive to patients’ use of, for example, mobile 
phones, which can affect treatment-seeking pathways and, potentially, 
antibiotic use.
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signature, we follow a verbal consent process in which (1) 
we seek permission from village leaders to carry out our 
survey in their villages; (2) the survey fieldworker reads out 
(and records on audio tape) an oral consent script to the 
potential respondent and provides them with a printed 
copy of the participant information sheet; (3) the survey 
fieldworker asks the respondent to state her or his consent, 
name and date on audio record and (4) the survey field-
worker personally signs and dates a written record of oral 
consent. We provide a detailed justification and explana-
tion of this verbal consent process in online Supplementary 
appendix 1.
Privacy and confidentiality
Further ethical considerations in this study relate to privacy 
and confidentiality. The data collected in this study include 
self-reported health and economic information. Personal 
contact details will be stored separately from the data sets in 
order to match data from repeated network survey rounds. 
Any identifying information will be deleted from the analyt-
ical data set or coded into anonymous respondent numbers 
for the social network census survey data set. Geographical 
data allowing household identification will be translated 
into distance measures and a village-centred metric coor-
dinate system (similar to the Universal Transverse Mercator 
system). Should village layouts prove idiosyncratic so that 
the metric coordinate system enables identification, we will 
withdraw these data from the data sets.
Proposed impact
The academic impact of our study pertains to antibiot-
ic-related behaviour and its relationship to marginalisa-
tion, technology and social relationships. Our innovations 
therein are theoretical (development of the activity space 
framework to conceptualise and situate people’s antibiotic 
access and use during illness), methodological (sequence 
analysis for healthcare pathways) and empirical (novel 
insights into the impact of marginalisation, technology and 
knowledge on antibiotic usage). In addition, we will build 
capacity for social research in AMR, for instance, through 
four internships for local candidates from Southeast Asia 
who consider interdisciplinary academic careers, and our 
project aims to influence the global health discourse about 
AMR, for example, by hosting four 8-week student place-
ments with the MSc International Health and Tropical 
Medicine (IHTM; a global health degree at the University 
of Oxford).
In conclusion, social research in AMR is nascent, but 
our unprecedentedly detailed data on microlevel treat-
ment-seeking behaviour promises to contribute to under-
standing behaviour beyond awareness and free choice, 
highlighting, for example, decision-making constraints, 
problems of marginalisation and lacking access to health-
care and competing ideas about desirable behaviour.
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